Showing results (121-130 of 136) with videos related to
Sort By:
Pageof 14
Journal of Gastroenterology|September 15, 2012
Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelinesNaoki Harada, Naoki Hiramatsu, Tsugiko Oze, et al.Translational Oncology|February 3, 2022
Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AMLKotoko Yamatani, Tomohiko Ai, Kaori Saito, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 23, 2015
Impact of branched-chain amino acid supplementation on survival in patients with advanced hepatocellular carcinoma treated with sorafenib: A multicenter retrospective cohort studyKazuho Imanaka, Kazuyoshi Ohkawa, Tomohide Tatsumi, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 6, 2016
Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infectionNaoki Morishita, Naoki Hiramatsu, Tsugiko Oze, et al.Journal of Medical Virology|March 19, 2016
Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapyYuki Tahata, Naoki Hiramatsu, Tsugiko Oze, et al.Nature Communications|February 25, 2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancerHayato Mizuta, Koutaroh Okada, Mitsugu Araki, et al.Investigational New Drugs|September 11, 2018
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patientsWon Young Tak, Baek-Yeol Ryoo, Ho Yeong Lim, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 11, 2013
Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapyTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2019
Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic responseRyoko Yamada, Naoki Hiramatsu, Tsugiko Oze, et al.Journal of Clinical Medicine Research|March 28, 2018
The Prevalence and Implication of Zinc Deficiency in Patients With Chronic Liver DiseaseKazuhiro Katayama, Takumi Kawaguchi, Koichi Shiraishi, et al.Pageof 14